Delix Therapeutics

Psychedelic medicine developer

Delix Therapeutics is an active clinical-stage neuroscience company developing non-hallucinogenic neuroplastogens for psychiatric, neurological, and neurodegenerative conditions. Its lead candidate, DLX-001 (zalsupindole), is an investigational isotryptamine inspired by 5-MeO-DMT; it completed a Phase Ib study for recurrent major depressive disorder, with Phase IIb planned for H1 2027. The company is headquartered in Bedford, Massachusetts, and no ownership change is reported in the supplied information. Its candidates are investigational and are not available to buy.

Website

delixtherapeutics.com

Delix Therapeutics catalog

All products · Psychedelic medicine pipeline

Shop the Delix Therapeutics catalog

1 item across 1 shelf

Psychedelic medicine pipeline1 item

• DLX-001 – ZalsupindoleInvestigational